<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Aplastic <z:hpo ids='HP_0001903'>anaemia</z:hpo> (AA) of the <z:hpo ids='HP_0011010'>chronic</z:hpo> type with severe cytopenia is very frequently a difficult therapeutic problem </plain></SENT>
<SENT sid="1" pm="."><plain>Patients with granulocyte values below 0.5 G/l are threatened by <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infections</z:e>, incl. <z:hpo ids='HP_0100806'>sepsis</z:hpo> possibly with a fatal outcome </plain></SENT>
<SENT sid="2" pm="."><plain>If the pool of stem cells for granulocytes is not completely exhausted and can respond to growth factors, these patients can be treated either chronically and/or in risk situations (e.g. injury, surgery) with preparations of the type of a recombinant, granulocyte colony stimulating factor (rhG-CSF), or granulocyte and monocyte colony stimulating factor (rhGM-CSF) </plain></SENT>
<SENT sid="3" pm="."><plain>The authors present a review of diagnostic and therapeutic algorithms in patients with the AA syndrome and summarize their own experience with the preparation Neupogen Roche (rhG-CSF) </plain></SENT>
</text></document>